{'fraction_non_alphanumeric': 0.05737199259716225, 'fraction_numerical': 0.03639728562615669, 'mean_word_length': 4.941391941391942, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Prognostic impact of the UK Myeloma Research Alliance Risk Profile in transplant-ineligible patients with multiple myeloma who received a melphalan, prednisolone, and bortezomib regimen: A supplementary analysis of JCOG1105.

The UK Myeloma Research Alliance Risk Profile (MRP) is a novel prognostic model for transplant-ineligible patients with multiple myeloma (MM). Since MRP was developed based on the results of clinical trials in which immunomodulatory drugs were used as induction regimens, its applicability to patients treated with bortezomib-based regimens remains elusive. The aim of this study is to assess the utility of MRP in patients treated with a representative bortezomib-based regimen of melphalan, prednisolone, and bortezomib (MPB) in JCOG1105, a randomized phase II trial comparing two modified MPB regimens. The patients (n=88) were categorized into MRP risk of low (59%), medium (18%), and high (23%). The median follow-up time was 3.9 years, and a higher MRP risk was not associated with poor overall survival (p=0.45). The 3-year OS of patients with low-, medium-, and high-risk of MRP was 84.3% (95% confidence interval [CI], 71.1-91.8%), 68.8% (95% CI, 40.5-85.6%), and 85.0% (95% CI, 60.4-94.9%), respectively. In conclusion, higher MRP risk groups were not significantly associated with poor prognosis in patients who received an MPB regimen in this supplementary analysis of JCOG1105. Large-scale studies which include patients treated with bortezomib-based regimens are required to further validate the significance of the MRP. This article is protected by copyright. All rights reserved.